Abstract

The overall objective of this contract is to evaluate control measures for infectious diseases other than AIDS. There are still many infectious diseases for which effective and highly safe vaccines and therapies have yet to be developed. Additionally, for some diseases improved vaccines are needed that will prevent infection and disease in age groups not currently protected and that will offer increased safety. New vaccine and drug candidates continue to be developed, spurred on by advances in the basic sciences. The capacity to evaluate these new and improved vaccine and therapy candidates in an efficient and expeditious manner is an essential element of the efforts of the Division of Microbiology and Infectious Diseases (DMID) of the National Institute of Allergy and Infectious Diseases (NIAID). This contract for a Vaccine and Treatment Evaluation Unit (VTEU) in an integral part of these efforts and supports Phase I and Phase II clinical trials of bacterial and viral vaccines, other biologicals, and drugs as preventative and therapeutic measures against infectious diseases in people of all ages and risk categories. In selected circumstances, Phase III vaccine trials may also be undertaken. Also of importance is the epidemiologic surveillance of pathogens that are of special interest to NIAID, and capacity to undertake limited, relevant, basic and preclinical research directly linked to vaccine biology and immunology.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research and Development Contracts (N01)
Project #
N01AI045250-008
Application #
2371294
Study Section
Project Start
1994-09-30
Project End
2001-09-29
Budget Start
1996-09-27
Budget End
1998-10-06
Support Year
Fiscal Year
1996
Total Cost
Indirect Cost

  Institution

Name
Saint Louis University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Saint Louis
State
MO
Country
United States
Zip Code
63103

  Publications

Belshe, Robert B; Heineman, Thomas C; Bernstein, David I et al. (2014) Correlate of immune protection against HSV-1 genital disease in vaccinated women. J Infect Dis 209:828-36
Schulte, Joann M; Bellamy, Abbie R; Hook 3rd, Edward W et al. (2014) HSV-1 and HSV-2 seroprevalence in the united states among asymptomatic women unaware of any herpes simplex virus infection (Herpevac Trial for Women). South Med J 107:79-84
Awasthi, Sita; Belshe, Robert B; Friedman, Harvey M (2014) Better neutralization of herpes simplex virus type 1 (HSV-1) than HSV-2 by antibody from recipients of GlaxoSmithKline HSV-2 glycoprotein D2 subunit vaccine. J Infect Dis 210:571-5
Bernstein, David I; Bellamy, Abbie R; Hook 3rd, Edward W et al. (2013) Epidemiology, clinical presentation, and antibody response to primary infection with herpes simplex virus type 1 and type 2 in young women. Clin Infect Dis 56:344-51
Belshe, Robert B; Leone, Peter A; Bernstein, David I et al. (2012) Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med 366:34-43
Brady, Rebecca C; Treanor, John J; Atmar, Robert L et al. (2009) Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults. Vaccine 27:5091-5
Flitter, Becca A; Ismail, Adil; Vu, David et al. (2007) Group A antibody persistence five years after meningococcal polysaccharide vaccination in the Sudan. Hum Vaccin 3:135-8
Laassri, Majid; Lottenbach, Kathleen; Belshe, Robert et al. (2006) Analysis of reversions in the 5'-untranslated region of attenuated poliovirus after sequential administration of inactivated and oral poliovirus vaccines. J Infect Dis 193:1344-9
Laassri, Majid; Dragunsky, Eugenia; Enterline, Joan et al. (2005) Genomic analysis of vaccine-derived poliovirus strains in stool specimens by combination of full-length PCR and oligonucleotide microarray hybridization. J Clin Microbiol 43:2886-94
Laassri, Majid; Lottenbach, Kathleen; Belshe, Robert et al. (2005) Effect of different vaccination schedules on excretion of oral poliovirus vaccine strains. J Infect Dis 192:2092-8

Showing the most recent 10 out of 29 publications